Esperion Therapeutics (ESPR) Cash from Operations Growth (5y) (2017 - 2026)
Esperion Therapeutics (ESPR) Cash from Operations Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.93 Bn | 32.19 Bn | 1.97 Bn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.43 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.82% |
| Dec 31, 2025 | 21.61% |
| Sep 30, 2025 | 45.19% |
| Jun 30, 2025 | -17.35% |
| Mar 31, 2025 | 20.07% |
| Dec 31, 2024 | 6.91% |
| Sep 30, 2024 | 9.45% |
| Jun 30, 2024 | 33.16% |
| Mar 31, 2024 | -10.10% |
| Dec 31, 2023 | -5.25% |
| Sep 30, 2023 | 12.43% |
| Jun 30, 2023 | 8.79% |
| Mar 31, 2023 | -4.69% |
| Dec 31, 2022 | -4.02% |
| Sep 30, 2022 | -3.60% |
| Jun 30, 2022 | -14.01% |
| Mar 31, 2022 | -2.59% |
| Dec 31, 2021 | -28.74% |
| Sep 30, 2021 | -37.05% |
| Jun 30, 2021 | -45.63% |